胰腺癌的新辅助治疗

Neoadjuvant therapy for pancreatic carcinoma

胰腺癌是一类恶性程度高、预后极差的消化系统肿瘤,其早期诊断及治疗始终是国内外学者研究的热点与难点。随着对胰腺癌研究的深入,胰腺癌的治疗理念也正从单纯外科学向肿瘤多学科团队协作转化。胰腺癌的新辅助治疗方兴未艾,希望能有效延长患者的生存期,但其在临床策略制定、放化疗方案选择、治疗周期及疗效预测等方面尚未达成共识,仍需通过大样本的前瞻性临床对照研究进行总结,并进一步客观评价新辅助治疗在改善胰腺癌患者远期生存中的作用。

Pancreatic carcinoma is a highly malignant digestive tumor associated with an extremely poor prognosis,and its early diagnosis and early treatment have always been the study focus areas and difficult tasks for scholars at home and abroad.As the investigations into pancreatic carcinoma deepen,the therapeutic concept of pancreatic carcinoma is also advancing from the pure surgery-first to multidisciplinary collaborative practice model.Neoadjuvant therapy of pancreatic carcinoma is emerging,and it is hoped to effectively prolong the survival time of the patients.However,no consensus has yet been reached with regard to its therapeutic strategy making,regimen selection,treatment cycles or therapeutic effect prediction.Many problems still need to be objectively verified by a series of randomized controlled trials with large sample size,and to the efficacy of neoadjuvant therapy in improving the long-term survival of pancreatic carcinoma patients should be further objectively assessed.